Latest From Xencor Inc.
The tireless pace of change in hemato-oncology was showcased in Orlando.
Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.
Immuno-oncology development trends are revealed through an analysis of deals between cancer drug developers over the past five years.
When approved therapies target the same antigens as the investigational bispecific antibody, FDA may request a comparative clinical trial, draft guidance notes.
- Large Molecule
- Therapeutic Areas
- Immune Disorders
- Infectious & Viral Diseases
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- Xencor Inc.
- Senior Management
Bassil I Dahiyat, PhD, Pres. & CEO
John Kuch, SVP, CFO
John R Desjarlais, PhD, SVP, Research & CSO
Jeremy Grunstein, PhD, VP, Bus. Dev.
- Contact Info
Phone: (626) 305-5900
111 W. Lemon Ave.
Monrovia, CA 91016
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.